ArticleFrontiers in oncology2020
The Effect of m6A Methylation Regulatory Factors on the Malignant Progression and Clinical Prognosis of Hepatocellular Carcinoma.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- PRMT5 inhibits the ferroptosis of hepatocellular carcinoma via regulating RBM15/FTH1 signaling.American journal of cancer research · 2026Article
- HNRNPA2B1 is a potential biomarker of breast cancer related to prognosis and immune infiltration.Aging · 2023Article
- Article
- NCancers · 2022Review
- Insight into the structure, physiological function, and role in cancer of m6A readers-YTH domain-containing proteins.Cell death discovery · 2022Review
- CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via mMolecular therapy oncolytics · 2022Article
- Identification and validation of a prognostic model of necroptosis-related lncRNAs in hepatocellular carcinoma.Frontiers in genetics · 2022Article
- The roles and mechanisms of the m6A reader protein YTHDF1 in tumor biology and human diseases.Molecular therapy. Nucleic acids · 2021Review
- YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition.Experimental hematology & oncology · 2021Article
- Identification of a Potential PPAR-Related Multigene Signature Predicting Prognosis of Patients with Hepatocellular Carcinoma.PPAR research · 2021Article
- Gene Expression Profile and Prognostic Value of m6A RNA Methylation Regulators in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2021Article
- N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma.Frontiers in cell and developmental biology · 2021Article
- Role of N6-Methyladenosine (mFrontiers in oncology · 2021Review
- DNASE1L3 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma Based on Data Mining.Frontiers in genetics · 2021Article
- Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma.Frontiers in molecular biosciences · 2021Article
- The emerging roles of mInternational journal of biological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The modification level of the transcript N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.